Altmetric

Nasal inflammation and its response to local glucocorticoid regular treatment in patients with persistent non-allergic rhinitis: a pilot study

File Description SizeFormat 
JINFD1600035R1 accepted version18July2016.docxAccepted version467.2 kBMicrosoft WordView/Open
art%3A10.1186%2Fs12950-016-0134-3.pdfPublished version947.6 kBAdobe PDFView/Open
Title: Nasal inflammation and its response to local glucocorticoid regular treatment in patients with persistent non-allergic rhinitis: a pilot study
Authors: Iannini, V
Casolari, P
Contoli, M
Papi, A
Kirkham, P
Hansel, TT
Chung, KF
Barnes, PJ
Pastore, A
Pelucchi, S
Adcock, IM
Caramori, G
Item Type: Journal Article
Abstract: Background The pathogenesis of non-allergic rhinitis (NAR) is still largely unknown. Furthermore, it is unclear whether there is a correlation between the effect of nasal glucocorticoids on nasal inflammation and on nasal symptoms and quality of life. Methods In this pilot study we recruited 12 healthy subjects and 24 patients with recently diagnosed persistent NAR [12 untreated and 12 under regular treatment with nasal fluticasone furoate (two sprays of 27.5 µg each in each nostril once daily, total daily dose=110 µg) for at least 20 days]. Each subject filled a mini rhinoconjunctivitis quality of life questionnaire (mini RQLQ). Nasal scrapings were obtained from each subject and used to prepare slides for Diff-Quik and immunocytochemical staining for inflammatory and epithelial cells count, MUC5AC expression and the general pro-inflammatory transcription factor nuclear factor B (NF-B) activation. Results The nasal score of the mini RQLQ, the number of nasal inflammatory cells (neutrophils, eosinophils) and the number of goblet cells are significantly higher in untreated patients with persistent NAR compared with control subjects and treated NAR patients. The percentage of MUC5AC+ nasal epithelial cells is significantly increased in untreated patients with persistent NAR compared with the control subjects (41.8±6.4 vs 22.3±4.8, respectively; p=0.0403) without significant differences between control subjects and patients with persistent NAR on regular fluticasone furoate treatment with nasal glucocorticoids (33.9±5.0%; p=0.0604) nor between the 2 groups of persistent NAR subjects (p=0.3260). The number of cytosolic and/or nuclear p65+ nasal epithelial and inflammatory cells was not significantly different between the three groups. Conclusions Patients with persistent untreated NAR, compared with normal control subjects and patients with persistent NAR under regular treatment with nasal fluticasone furoate glucocorticoids by at least 20 days, have more nasal symptoms, worst quality of life and an increased number of nasal inflammatory cells (neutrophils, eosinophils), goblet cells and MUC5AC+ nasal epithelial cells. This nasal inflammation seems unrelated to NF-κB activation.
Issue Date: 4-Aug-2016
Date of Acceptance: 28-Jul-2016
URI: http://hdl.handle.net/10044/1/37581
DOI: http://dx.doi.org/10.1186/s12950-016-0134-3
ISSN: 1476-9255
Publisher: BioMed Central
Journal / Book Title: Journal of Inflammation
Volume: 13
Copyright Statement: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords: Immunology
Clinical Sciences
Pharmacology And Pharmaceutical Sciences
Publication Status: Published
Article Number: 26
Appears in Collections:National Heart and Lung Institute
Airway Disease
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons